Abstract
AbstractA short introduction to the use of whole-body hyperthermia (WBH) in oncology is provided. The main focus is on fever-range whole-body hyperthermia (FRWBH), since various preclinical studies have shown promising results using this approach. However, FRWBH has not been comprehensively investigated in clinical oncology trials. Having provided an overview on the methods to induce WBH, we will summarize preclinical and clinical data on the mode of action of FRWBH. The latter treatment positively affects the tumor micromilieu, especially by decreasing tumor hypoxia. It has the potential to enhance tumor-directed immune reactions and has proven anti-depressive and potential analgesic effects in patients without cancer. These pleiotropic effects align with good tolerability and high acceptability by patients. Given the available evidence, we argue that FRWBH should be investigated as an adjunct to modern cancer treatments in controlled clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
